Nothing Special   »   [go: up one dir, main page]

MA47233A - Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation - Google Patents

Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation

Info

Publication number
MA47233A
MA47233A MA047233A MA47233A MA47233A MA 47233 A MA47233 A MA 47233A MA 047233 A MA047233 A MA 047233A MA 47233 A MA47233 A MA 47233A MA 47233 A MA47233 A MA 47233A
Authority
MA
Morocco
Prior art keywords
methods
substituted heterocyclic
compounds used
heterocyclic compounds
amine substituted
Prior art date
Application number
MA047233A
Other languages
English (en)
Inventor
Kenneth William Duncan
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MA47233A publication Critical patent/MA47233A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA047233A 2016-12-19 2017-12-19 Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation MA47233A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436139P 2016-12-19 2016-12-19
US201762517840P 2017-06-09 2017-06-09

Publications (1)

Publication Number Publication Date
MA47233A true MA47233A (fr) 2019-10-23

Family

ID=60972416

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047233A MA47233A (fr) 2016-12-19 2017-12-19 Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation

Country Status (24)

Country Link
US (2) US20200039998A1 (fr)
EP (2) EP3555070B1 (fr)
JP (2) JP2020504715A (fr)
KR (1) KR102693367B1 (fr)
CN (2) CN110088099B (fr)
AU (3) AU2017382830A1 (fr)
BR (1) BR112019012140A2 (fr)
CA (1) CA3045032A1 (fr)
CL (2) CL2019001664A1 (fr)
CO (1) CO2019006787A2 (fr)
DK (1) DK3555070T3 (fr)
ES (1) ES2955132T3 (fr)
FI (1) FI3555070T3 (fr)
HU (1) HUE063405T2 (fr)
IL (1) IL267090A (fr)
LT (1) LT3555070T (fr)
MA (1) MA47233A (fr)
MX (1) MX2019007234A (fr)
PL (1) PL3555070T3 (fr)
PT (1) PT3555070T (fr)
SG (1) SG10201913464TA (fr)
SI (1) SI3555070T1 (fr)
TW (2) TWI808067B (fr)
WO (1) WO2018118842A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
JP7187449B2 (ja) * 2016-09-30 2022-12-12 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物
CN110719781A (zh) * 2017-02-14 2020-01-21 效应治疗股份有限公司 取代的哌啶MnK抑制剂及其相关方法
WO2018183923A1 (fr) * 2017-03-31 2018-10-04 Epizyme, Inc. Procédés d'utilisation d'inhibiteurs d'ehmt2
AU2018254577B2 (en) 2017-04-21 2024-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
AU2018301681B2 (en) 2017-07-14 2022-07-14 Innate Tumor Immunity, Inc. NLRP3 modulators
JP7425724B2 (ja) * 2017-10-17 2024-01-31 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体
MX2020007152A (es) * 2017-10-18 2020-12-10 Epizyme Inc Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
CN111315371A (zh) * 2017-10-18 2020-06-19 埃皮兹姆公司 使用ehmt2抑制剂治疗或预防血液障碍的方法
US11130757B2 (en) 2018-10-24 2021-09-28 Effector Therapeutics Inc. Crystalline forms of MNK inhibitors
CN113286787A (zh) * 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
JP2022527279A (ja) * 2019-03-28 2022-06-01 エピザイム，インコーポレイティド キノリン誘導体及び癌の治療のためのその使用
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
MX2024004416A (es) * 2021-10-15 2024-07-09 Tango Therapeutics Inc Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos.
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2024019541A1 (fr) * 2022-07-20 2024-01-25 일동제약(주) Composé dérivé d'hétéroaryle et son utilisation
CN115974727B (zh) * 2023-01-17 2024-03-12 青岛前线生物工程有限公司 一种联苯肼酯的合成方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO2000025780A1 (fr) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Composes derives d'un noyau amine inhibiteurs de l'enzyme impdh
US6596747B2 (en) * 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
WO2003004492A1 (fr) * 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines utilisees en tant qu'inhibiteurs des proteines kinases src et lck
WO2003040141A1 (fr) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Composes d'oxazolyl-phenyl-2,4-diamino-pyrimidine, et methodes de traitement de troubles hyperproliferatifs
WO2005013996A2 (fr) 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. Composes de 2,4-pyrimidinediamine et leurs utilisations comme agents antiproliferants
JP2009501164A (ja) * 2005-07-15 2009-01-15 ４エスツェー アクチェンゲゼルシャフト ２−アリールベンゾチアゾール及びその使用
BRPI0620408B8 (pt) * 2005-12-21 2021-05-25 Novartis Ag derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
AR065015A1 (es) * 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
JP5586460B2 (ja) * 2007-07-17 2014-09-10 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｐｋｃ阻害剤としての環状アミン置換ピリミジンジアミン
MX2010008700A (es) * 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
NZ594323A (en) * 2009-01-23 2013-05-31 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
TW201040162A (en) 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
WO2014044025A1 (fr) * 2012-09-20 2014-03-27 山东亨利医药科技有限责任公司 Dérivé de pyrimidinamide et son procédé de préparation et son utilisation
WO2014089112A1 (fr) * 2012-12-04 2014-06-12 Rigel Pharmaceuticals, Inc. Inhibiteurs de la protéine kinase c et utilisations de ceux-ci
CA2904610A1 (fr) * 2013-03-14 2014-09-25 Rigel Pharmaceuticals, Inc. Inhibiteurs de proteine kinase c et leurs utilisations
WO2014152768A1 (fr) * 2013-03-15 2014-09-25 Portola Pharmaceuticals, Inc. Composés de cyclohexanediamine et leurs procédés de préparation
WO2016175264A1 (fr) * 2015-04-28 2016-11-03 カルナバイオサイエンス株式会社 Nouveau dérivé hétéroaryle présentant une activité antipaludique
EP3442947B1 (fr) * 2016-04-15 2023-06-07 Epizyme, Inc. Dérivés d'aryl ou heteroaryl substitués par une amine comme inhibiteurs de ehmt1 et ehmt2
CN106083828A (zh) * 2016-06-30 2016-11-09 浙江大学 含吖丙啶环侧链的芳胺嘧啶衍生物及制备和应用

Also Published As

Publication number Publication date
EP4285906A2 (fr) 2023-12-06
ES2955132T3 (es) 2023-11-28
CA3045032A1 (fr) 2018-06-28
AU2024205290A1 (en) 2024-08-22
AU2022202494B2 (en) 2024-05-02
CN110088099B (zh) 2023-01-31
EP4285906A3 (fr) 2024-03-13
SG10201913464TA (en) 2020-03-30
TW201833102A (zh) 2018-09-16
TW202411220A (zh) 2024-03-16
PL3555070T3 (pl) 2023-11-06
HUE063405T2 (hu) 2024-01-28
CN110088099A (zh) 2019-08-02
KR102693367B1 (ko) 2024-08-12
CL2020001133A1 (es) 2020-11-06
MX2019007234A (es) 2019-09-06
BR112019012140A2 (pt) 2019-11-05
JP2022110080A (ja) 2022-07-28
LT3555070T (lt) 2023-09-11
TWI808067B (zh) 2023-07-11
US20220235065A1 (en) 2022-07-28
WO2018118842A1 (fr) 2018-06-28
SI3555070T1 (sl) 2023-11-30
EP3555070A1 (fr) 2019-10-23
US20200039998A1 (en) 2020-02-06
PT3555070T (pt) 2023-09-14
EP3555070B1 (fr) 2023-08-09
CN116041346A (zh) 2023-05-02
KR20190092542A (ko) 2019-08-07
JP2020504715A (ja) 2020-02-13
CO2019006787A2 (es) 2019-09-30
AU2022202494A1 (en) 2022-05-12
CL2019001664A1 (es) 2019-12-06
AU2017382830A1 (en) 2019-06-13
IL267090A (en) 2019-08-29
DK3555070T3 (da) 2023-09-18
FI3555070T3 (fi) 2023-09-12

Similar Documents

Publication Publication Date Title
MA47233A (fr) Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
FR24C1009I1 (fr) Composés utilisés comme inhibiteurs de kinase
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
MA43284A (fr) Composés et leurs méthodes d'utilisation
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA52119A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA44666A (fr) Composés aryle ou hétéroaryle à substitution amine utilisés comme inhibiteurs de ehmt1 et ehmt2
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA50418A (fr) Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse
MA52939A (fr) Composés inhibiteurs d'oga
MA40534B1 (fr) Inhibiteurs de mk2 et leurs utilisations
MA44008A (fr) 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b
MA47420A (fr) Composés inhibiteurs d'oga
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA43998A (fr) 2-(het)aryl-imidazolyl-carboxamides substitués utilisés comme pesticides
MA51864A (fr) Méthodes d'identification de composés
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA50145A (fr) Composés inhibiteurs de vmat2 et compositions de ceux-ci